Hepatitis Monthly

Published by: Kowsar

Interpretation of Serum Visfatin Level in Relation to Hepatic Injury is Probably Gender Dependent in Nonalcoholic Fatty Liver Disease

Bahareh Amirkalali 1 , Masoud Reza Sohrabi 1 , Ali Gholami 2 , 3 , Payam Hosseinzadeh 1 , Farzad Shidfar 4 , * and Farhad Zamani 1 , **
Authors Information
1 Gastrointestinal and Liver Disease Research Center (GILDRC), Iran University of Medical Sciences, Tehran, Iran
2 Department of Public Health, School of Public Health, Neyshabur University of Medical Sciences, Neyshabur, Iran
3 Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
4 Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: July 2017, 17 (7); e13242
  • Published Online: July 23, 2017
  • Article Type: Research Article
  • Received: November 6, 2016
  • Revised: March 4, 2017
  • Accepted: April 30, 2017
  • DOI: 10.5812/hepatmon.13242

To Cite: Amirkalali B, Sohrabi M R, Gholami A, Hosseinzadeh P, Shidfar F, et al. Interpretation of Serum Visfatin Level in Relation to Hepatic Injury is Probably Gender Dependent in Nonalcoholic Fatty Liver Disease, Hepat Mon. 2017 ; 17(7):e13242. doi: 10.5812/hepatmon.13242.

Abstract
Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9(6): 524-30[DOI][PubMed]
  • 2. Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, et al. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol. 2016; 22(10): 3023-30[DOI][PubMed]
  • 3. Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013; 28 Suppl 1: 11-7[DOI][PubMed]
  • 4. Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010; 9: 42[DOI][PubMed]
  • 5. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009; 9(4): 782-93[DOI][PubMed]
  • 6. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2013; 108(1): 222-8[DOI][PubMed]
  • 7. Mirza MS. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011; 2011: 592404[DOI][PubMed]
  • 8. Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol. 2013; 12(4): 548-55[PubMed]
  • 9. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14(2): 1431-7[PubMed]
  • 10. Yang H, Lavu S, Sinclair DA. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol. 2006; 41(8): 718-26[DOI][PubMed]
  • 11. Yang CC, Deng SJ, Hsu CC, Liu BH, Lin EC, Cheng WT, et al. Visfatin regulates genes related to lipid metabolism in porcine adipocytes. J Anim Sci. 2010; 88(10): 3233-41[DOI][PubMed]
  • 12. Akbal E, Kocak E, Tas A, Yuksel E, Koklu S. Visfatin levels in nonalcoholic fatty liver disease. J Clin Lab Anal. 2012; 26(2): 115-9[DOI][PubMed]
  • 13. Auguet T, Terra X, Porras JA, Orellana-Gavalda JM, Martinez S, Aguilar C, et al. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin Biochem. 2013; 46(3): 202-8[DOI][PubMed]
  • 14. Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016; 17(1): 68-80[DOI][PubMed]
  • 15. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci. 2009; 54(8): 1772-7[DOI][PubMed]
  • 16. Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damas JK, et al. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2010; 95(6): 3039-47[DOI][PubMed]
  • 17. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008; 27(5): 412-21[DOI][PubMed]
  • 18. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008; 18(11): 1430-7[DOI][PubMed]
  • 19. MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab. 2007; 9(4): 490-7[DOI][PubMed]
  • 20. Zhou J, Seidel ER. Estrogens induce visfatin expression in 3T3-L1 cells. Peptides. 2010; 31(2): 271-4[DOI][PubMed]
  • 21. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 2012; 19(4): 244-53[DOI][PubMed]
  • 22. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29(12): 1705-13[PubMed]
  • 23. Sanyal AJ, American Gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5): 1705-25[PubMed]
  • 24. Esmaillzadeh A, Mirmiran P, Azizi F. Whole-grain intake and the prevalence of hypertriglyceridemic waist phenotype in Tehranian adults. Am J Clin Nutr. 2005; 81(1): 55-63[PubMed]
  • 25. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 35(8): 1381-95[DOI][PubMed]
  • 26. McDowell MA, Statistics NCH. Anthropometric reference data for children and adults: Us population, 1999-2002: Us department of health and human services, centers for disease control and prevention. 2005;
  • 27. Bowlby SC, Thomas MJ, D'Agostino RB, Kridel SJ. Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. PLoS One. 2012; 7(6): 40195[DOI][PubMed]
  • 28. Ali Mohammad S, Nawas SS, Siddiqui IA, Sasikala M, Mukarjee RM, Rao N. Circulating visfatin and proinflammatory cytokine levels in nonalcoholic fatty liver disease. Int J Curr Res. 2014; 6(8): 8159-62
  • 29. Lee JJ, Lambert JE, Hovhannisyan Y, Ramos-Roman MA, Trombold JR, Wagner DA, et al. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr. 2015; 101(1): 34-43[DOI][PubMed]
  • 30. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115(5): 1343-51[DOI][PubMed]
  • 31. Solinas G, Boren J, Dulloo AG. De novo lipogenesis in metabolic homeostasis: More friend than foe? Mol Metab. 2015; 4(5): 367-77[DOI][PubMed]
  • 32. Minehira K, Vega N, Vidal H, Acheson K, Tappy L. Effect of carbohydrate overfeeding on whole body macronutrient metabolism and expression of lipogenic enzymes in adipose tissue of lean and overweight humans. Int J Obes Relat Metab Disord. 2004; 28(10): 1291-8[DOI][PubMed]
  • 33. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care. 2001; 4(6): 499-502[PubMed]
  • 34. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol. 2006; 95(3): 136-47[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments